Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)

Trial Profile

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Levofloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Apr 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
    • 22 Jul 2013 Planned End Date changed from 1 Mar 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top